Share on StockTwits
 

Investment analysts at Mizuho began coverage on shares of Oncomed Pharmaceuticals (NASDAQ:OMED) in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.

OMED has been the subject of a number of other recent research reports. Analysts at Piper Jaffray raised their price target on shares of Oncomed Pharmaceuticals to $48.00 in a research note on Friday, January 17th. Analysts at Jefferies Group raised their price target on shares of Oncomed Pharmaceuticals from $27.00 to $46.00 in a research note on Wednesday, December 4th. They now have a “buy” rating on the stock. Four analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average target price of $42.00.

Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded up 5.57% during mid-day trading on Monday, hitting $31.47. The stock had a trading volume of 206,150 shares. Oncomed Pharmaceuticals has a one year low of $12.07 and a one year high of $42.34. The stock’s 50-day moving average is $31.93 and its 200-day moving average is $20.90. The company’s market cap is $878.0 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last released its earnings data on Tuesday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.12 by $0.27. Analysts expect that Oncomed Pharmaceuticals will post $-0.60 EPS for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.